Silver Spring, Md. (PRWEB)
May 18, 2017
Researchers will present two abstracts based on information from the Pulmonary Hypertension Association Registry (PHAR) at the American Thoracic Society (ATS) meeting this month. The PHAR is a part of the Pulmonary Hypertension Association (PHA) Pulmonary Hypertension Care Center (PHCC) accreditation program.
Pulmonary arterial hypertension (PAH)—a progressive, life-threatening, debilitating form of PH—is high blood pressure of the lungs due to narrowing of the pulmonary arteries. It forces the right side of the heart to pump so hard to move blood into the lungs that it can lead to heart failure. Symptoms are non-specific and include shortness of breath, fatigue and chest pain. Because patients go months, sometimes years, believing they have something other than PH, most patients are ultimately diagnosed with an advanced form of the disease. But early and accurate diagnosis, quality care and appropriate PAH treatments can extend and improve the quality of life for many patients.
With the recent addition of the three adult-treating Regional Clinical Programs (RCP), 50 programs (including six pediatric and forty-one adult Centers of Comprehensive Care (CCCs) in 27 states across the U.S. have earned accreditation since the quality improvement initiative launched less than three years ago. To continue striving for better quality of care in the treatment of PH, the PHCC program encourages all accredited sites to participate in the PHAR. As of May 2017, 18 accredited sites are participating in the PHAR and have already enrolled 253 patients.
At the upcoming ATS meeting in Washington D.C. , on behalf of the entire PHAR study group investigators,* Roham T. Zamanian, MD (Stanford University) will present “Determinants of Health Related Quality of Life…